Daewoong Pharma, UK firm to jointly develop autoimmune disease drug

This company will strengthen its capabilities in protein-protein interaction new drug with UK’s Signature Discovery

Daewoong Pharma, UK firm to jointly develop autoimmune disease drug
Jeong-Min Nam 1
2023-04-18 18:03:56 peux@hankyung.com
Bio & Pharma

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British new drug developer, to discover new candidate substances for autoimmune disease treatments.

Under the agreement, Daewoong Pharmaceutical will use Sygnature's new drug discovery technology to discover new candidate substances for autoimmune disease treatments and strengthen its capabilities in protein-protein interaction (PPI) new drug development. The agreement also includes support for efficacy and mechanism validation and development acceleration.

Sygnature is a new drug development partner that supports early-stage drug development and research, founded in 2004.

Park Joon-seok, head of Daewoong Pharmaceutical's New Drug Development Center, said, "Daewoong Pharmaceutical is actively promoting open collaboration for more effective global new drug development through innovative platform technologies," and expressed expectations that "this cooperation will provide a new milestone in expanding our new drug pipeline."

Write to Jeong-Min Nam at peux@hankyung.com
##Daewoong Pharmaceutical Sygnature Discovery

Daewoong Pharma's Fexuclue safe to use with aspirin: Clinical trials

Daewoong Pharma's Fexuclue safe to use with aspirin: Clinical trials

Daewoong Pharmaceutical's Fexuclue Daewoong Pharmaceutical Co., a leading South Korean pharmaceutical company, has announced the successful completion of phase 1 clinical trials for Fexuclue (fexuprazan), a potassium-competitive acid blocker (P-CAB)-based drug used to treat gastroesophageal r

Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

Daewoong Pharmaceutical headquarters in Seoul (Courtesy of Daewoong) South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exporting it to Brazil and Mexico.Through the $84.4 million deal, the Korean biotech w

Korean court rules Daewoong poached Medytox’s botox strain

Korean court rules Daewoong poached Medytox’s botox strain

Korean botox maker Medytox A South Korean court on Friday ruled in favor of Medytox Inc. in a civil lawsuit against its crosstown rival Daewoong Pharmaceutical Co. over the source of its botulinum toxin, more commonly known as botox.The Seoul Central District Court accepted Medytox’s clai

Daewoong Pharma wins permission from Singapore for Nabota

Daewoong Pharma wins permission from Singapore for Nabota

Daewoong Phamaceutical's Nabota South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) from Singapore authorities.The item that received approval this

Daewoong receives approval for its GERD drug Fexuclue in Ecuador

Daewoong receives approval for its GERD drug Fexuclue in Ecuador

Daewoong Pharmaceutical's Fexuclue Daewoong Pharmaceutical said Friday that it has obtained marketing authorization from Ecuador's National Agency for Health Regulation, Control and Surveillance (ARCSA) for its gastroesophageal reflux disease drug Fexuclue (active ingredient: Fexuprazan).This i
(* comment hide *}